IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

M. BORIN

09/759,056

Group Art Unit:

1631

Filed:

JANUARY 11, 2001

PENNICA ET AL.

Docket:

11669.163USU1

Confirmation No.:

1938

Title:

NOVEL STRA6 POLYPEPTIDES

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450 on October 20, 2004.

Name:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

Transmittal Sheet in duplicate containing Certificate of Mailing

Supplemental Information Disclosure Statement, Form 1449, 81 Reference(s), and fee of \$180.00

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C. P.O. Box 2903, Minneapolis, MN 55402-0903 612.332.5300

Name: Anne M. Murphy

Reg. No.: 54,327 AMurphy:PLSklg



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

PENNICA ET AL.

Examiner:

M. BORIN

Serial No.:

09/759,056

Group Art Unit:

1631

Filed:

JANUARY 11, 2001

Docket No.:

11669.163USU1

Title:

NOVEL STRA6 POLYPEPTIDES

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450 on October 29 2004.

By:

Name:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C. P. O. Box 2903 Minneapolis, Minnesota 55402-0903 612.332.5300

Date / Date / 2004

Anne M. Murphy

Reg. No. 54,327 AMM:PLSklg

23552

PATENT TRADEMARK OFFICE

FOR THE MATION I	DISCLOSURE STATEMENT	Docket Number: 11669.163USU1	Application Number: 09/759,056
OCT 2 2 2004 IN AN	APPLICATION	Applicant: PENNICA ET AL.	Confirmation No. 1938
91	al sheets if necessary)	Filing Date: 01/11/2001	Group Art Unit: 1631

TRADENT	<u> </u>			U.S. PATENT DOCUMENT				
EXAMINER INITIAL		DOCUMENT NO.		NAME	CLASS	SUBCLASS		G DATE OPRIATE
	6,187,819		02/13/2001	Fisher et al.				
•							. .	
	<u></u>		FOI	DEICNI DATENT DOCUMI	PAITE	<u> </u>		
	DOCUM	ENT NO	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION
	WO 95/322		11/30/1995	PCT	CEASS	J G D G D A T S D	YES	NO
	WO 98/549		12/10/1998	PCT				1 11
	WO 99/471		09/23/1999	PCT	-	<u> </u>		
	WO 01/126	-	02/22/2001	PCT	<u> </u>			
								
		ОТНЕ	R DOCUMENT	S (Including Author, Title, D	ate, Pertinent Pa	ges, Etc.)		
	,	Database EMBL 'Online! Entry/Acc.No. Al684707 28 May, 1999 STRAUSBERG R.: "wa85I NFL_T_GBC_S1 Homo Sapiens cDNA clone image:2302939 3'. mRNA sequence." XP0021' Database EMBL 'Online! Entry/Acc.No. A17601070 30 June, 1999 STRAUSBERG R.: "wg5 F8.9W_OT_PA_P_S1 Homo Sapiens cDNA clone image:2369315 3'. mRNA sequence." XP0 Aquino et al., "Effect of the Combined Treatment with 5-Fluorouracil, γ-Interferon or Folinic Carcionoembryonic Antigen Expression in Colon Cancer Cells", Clinical Cancer Research, 4(1998)						
						AUSBERG R.: "wg. RNA sequence." XP	58f06.X1 Soar 002174858 -	es-NSF-
	В		Barker et al., "The Yin-Yang of TCF/β-Catenin Signaling", Adv. Cancer Res., 77:1-24 (2000)					
	Beckmann et al., "Molecular characterization of a family of ligands for eph-related tyrosine k 13:3657 (1994)				cinase receptors", EMBO J.,			
	Behrens et al., "Functional Interaction of β-catenin with the transcription factor LEF-1", Nature, 382:6					<u>ıre,</u> 382:638-64	42 (1996)	
				n of Teo Novel WNT Genes, WNT14 and wnt15, One of Which (WNT15) Is Closely linked to mosome 17q21", Genomics, 46:450-458 (1997)				
		Bidyut Roy et al., "Synergistic Activation of Retinoic Acid (RA)-Responsive Genes and Induction of Carcinoma Cell Differentiation by a RA Receptor α (RARα)-, RARβ- or RARγ-Selective Ligand in Comb Retinoid X Receptor-Specific Ligand" Mol. Cell. Biol., 15(12):6481-7 (1995)						
				equence Comparison Method cad. Sci., 95:6073-6078 (Ma		tructurally identified	l distant evolut	ionary
			"A novel huma 14:1249-1253 (1	in Wnt gene, WNT10B, ma 997)	ps to 12q13 an	d is expressed in	human breast	carcinomas",
				coxycytidine induces growth cells", <u>Annals of Oncology</u> , 5			rmal growth fa	actor receptor
				Cloning of the Human Proto enomics, 18:249-260 (1993)	-oncogene Wnt-	-5A and Mapping	of the Gene ((WNTSA) to
				Retinoic Acid Upregulates th xical Teratol, 20:591-599 (19		COUP-TFI in Ear	ly-Somite Mo	use Embryos

EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED
<u></u>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Docket Number: Application Number: 11669.163USU1 09/759,056

IN AN APPLICATION Applicant: PENNICA ET AL. Confirmation No. 1938

(Use several sheets if necessary) Filing Date: 01/11/2001 Group Art Unit: 1631

la.	2)	(Ose several sneets if necessary)	Fining Date: 01/11/2001	Group Art Offit. 1031				
TRADE!								
& TRAUE		OTHER DOCUMENTS (Including Author,						
		Davis et al., "Ligands for EPH-Related Receptor for Activity", Science, 266:816 (1994)	r Tyrosine Kinases That Require	Membrane Attachment or Clustering				
			Dennis et al., "A secreted Frizzled related protein, FrzA, selectively associates with Wnt-1 protein and regulates Wnt-1 signaling", <u>Journal of Cell Science</u> , 112:3814-3820 (1999)					
		Donehower et al., "Deficiency of p53 accelere chromosomal instability", Genes Dev., 9:882-89		Wnt-1 transgenic mice and promotes				
		Drebin et al., "Monoclonal antibodies identify Nature, 312(5994):545-8 (1984)	a cell-surface antigen associated v	with an activated cellular oncogene",				
		Duester, Gregg, "Families of retinoid dehydroge retinoic acid", <u>Eur. J. Biochem.</u> , 267:4315-4324		n production of visual pigment and				
		Fear et al., "Wnt-16a, a Novel Wnt-16 Isoform, Biochem. Biophys. Res. Commun., 278:814-820		ion in Adult Human Tissues",				
		Glennie et al., "Clinical trials of antibody therap	nical trials of antibody therapy", Immunol. Today, 21:403-410 (2000)					
		He et al., "Identification of c-MYC as a Target o	f the APC Pathway", Science, 281	1509-1512 (1998)				
		Huguet et al., "Differential Expression of Human disease States of Human Breast Tissue", Cancer		an Breast Cell Lines and Normal and				
		Ikegawa et al., "Isolation, characterization and cl Genet., 74:149-152 (1996)	nromosomal assignment of the hun	nan WNT7A gene", Cytogenet. Cell.				
		Kantor et al., "Modulation of Carcinoembryonic Recombinant Human y-Interferon", Cancer Rese		n Human Colon Carcinoma Cells by				
		Katoh et al., "Cloning expression and chromosor Oncogene, 13:873-876 (1996)	nal localization of Wnt-13, a novel	member of the Wnt gene family",				
		Kim et al., "Anti4-IBB Monoclonal Antibodies E Draining Lymph Node Cells", <u>Proc. Am. Assoc.</u> Meeting of the American Association for Cancer	Cancer Res., 41, 91 Meet., 290, 20	000 (Conference abstract:91st Annual				
		Koj et al., "Regulation of Synthesis of Some Pro Hepatocyte Growth Factor", <u>Biol. Chem. Hoppe.</u>		ome Cells HepG2 by Cytokines,				
		Korinek et al., "Constitutive Transcriptional Acti Science, 275:1784-1787 (1997)	vation by a β-Catenin-Tcf Comple	ex in APC-/-Colon Carcinoma",				
		Lako et al., "Isolation, characterization and embr possible roles in the development of skeleton, kid						
		Lako et al., "Isolation and Characterization of W 35:386-388 (1996)	NT8B, a Novel Human Wnt Gene	That Maps to 10q24", Genomics,				
		Lee et al., "Cloning, Chromosomal Localization, Cells", <u>Biochem. Biophys. Res. Commun.</u> , 218:7	and Tissue Expression of Autotax 14-719 (1996)	in from human Teratocarcinoma				
		Martin-Satue et al., "Identification of Semaphoris by mRNA Differential Display", J. Surg. Oncol.,	•	Human Lung Adenocarcinoma Cells				
		McWhirter et al., "Oncogenic homeodomain tran lymphoblastoid leukemia", <u>Proc. Natl. Acad. Sci</u>		es a novel WNT gene in pre-B acute				
		Miller et al., "Signal transduction through β-cate 10:2527-2539 (1996)	nin and specification of cell fate du	ring embryogenesis", Genes & Dev.,				
		Morin et al., "Activation of β-Catenin-Tcf Signal 275:1787-1790 (1997)	ing in Coloon Cancer by Mutation	s in β-Catenin or APC", <u>Science</u> ,				

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Docket Number: Application Number: 11669.163USU1 09/759,056

IN AN APPLICATION Applicant: PENNICA ET AL. Confirmation No. 1938

(Use several sheets if necessary) Filing Date: 01/11/2001 Group Art Unit: 1631

	(Use several sheets if necessary)	Filing Date: 01/11/2001	Group Art Unit: 1631				
TRADEMAN	7						
TRADEMP	OTHER DOCUMENTS (Including	Author, Title, Date, Pertinent Pages, Etc					
	Moss, "Nomenclature of Retinoids", <u>Bio</u> 1992, pp 247-251	chemical Nomenclature and Related Doc	uments, 2 nd edition, Portland Press,				
	Moss, "Nomenclature of Retinoids", Pur	e Appl. Chem., 55:721-726 (1983)	<u> </u>				
	Moss, "Nomenclature of Retinoids", <u>Eur. J. Biochem.</u> , 129:1-5 (1982)						
	Moss, "Nomenclature of Retinoids", J. E	Moss, "Nomenclature of Retinoids", <u>J. Biol. Chem.</u> , 258:5329-5333 (1983) Moss, "Nomenclature of Retinoids", <u>Arch. Biochem. Biophys.</u> , 224:728-731 (1983)					
	Moss, "Nomenclature of Retinoids", Arc						
		Murata et al., "cDNA Cloning of the Human Tumor Motility-stimulating Protein, Autotaxin, Reveals a Phosphodiesterases", J. Biol. Chem., 269:30479-30484 (1994)					
	Nagasawa et al., "Cloning of the cDNA Leucine-Rich Repeat (LRR)", Genomics	for a New Member of the Immunoglobuli , 44:273-279 (1997)	n Superfamily (ISLR) Containing				
	Nagasawa et al., "Human and Mouse ISI Genomic Structure and Tissue Expression	LR (Immunoglobulin Superfamily) Conta on", <u>Genomics</u> , 61:37-43 (1999)	ining Leucine-Rich Repeat Genes:				
	Nagpal and Chandraratna, "Retinoids as Anti-Cancer Agents", <u>Current Pharmaceutical Design</u> , Benthar Publishers, 2:295-316 (1996) Nam et al., "Autotaxin 9ATX), a potent tumor motogen, augments invasive and metastatic potential of cells", <u>Oncogene</u> , 19:241-247 (2000) Nusse et al., "Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrat Region of the Host Genome", <u>Cell</u> , 31:99-109 (1982)						
	Palacios et al., "Mutations in the β-Cater 58:1344-1347 (1998)	rian Carcinomas", <u>Cancer Res.</u> ,					
	Pearson et al., "Differential Regulation of Chem., 267:25364-25370 (1992)	f Biglycan and Decorin by Retinoic Acid	in Bovine Chondrocytes", <u>J. Biol.</u>				
	Peifer et al., "Wnt Signaling in Oncogen 1609 (2000)	le the Nucleus", <u>Science</u> , 287:1606-					
	Polakis, Paul, "Wnt signaling and cancer	", Genes Dev., 14:1837-1851 (2000)					
	Prete et al., "Drug-Induced Changes of C Fluorouracil", Journal of Pharmacology						
	Rankin et al., "Partial cloning and assign Cytogenet. Cell. Genet., 84:50-52 (1999)	ment of WNT6 to human chromosome ba	and 2q35 by in situ hybridization"				
	Phosphorylation Are Differentially Invol	Rochette-Egly et al., "The AF-1 and AF-2 Activating Domains of Retinoic Acid Receptor-α (RAR-α) ar Phosphorylation Are Differentially Involved in Parietal Endodermal Differentiation of F9 Cells and Reti Expression of Target Genes", Mol. Endocrinol., 14(9):1398-1410 (2000)					
	Roelink et al., "Molecular Cloning and C 17:790-792 (1993)	Chromosomal Localization to 17q21 of the	e Human WNT3 Gene", Genomics,				
	Roose et al., "Synergy Between Tumor Suppressor APC and the β-Catenin-Tcf4 target Tcf1", Sc (1999)						
	Rubinfeld et al., "Stabilization of β-Cate (1997)	nin by Genetic Defects in Melanoma Cell	Lines", <u>Science</u> , 275:1790-1792				
	Sakanaka et al., "New steps in the Wnt/beta-catenin signal transduction pathway", Recent Pro (2000)						
		Wnt Family Members during Neuroector ssion of Wnt-1 Pertimbs Normal Differen					

	T
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Date Mailed: October 20, 2004

Customer No. 23552 Application Number:

Docket Number: 09/759,056 11669.163USU1 Confirmation No. 1938

Applicant: PENNICA ET AL. Filing Date: 01/11/2001

Group Art Unit: 1631

NFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

	(Use several sheets if necessary)	Filing Date: 01/11/2001	Group Art Unit: 1631				
TRADEMARK	OTHER DOCUMENTS (Including Author)	or, Title, Date, Pertinent Pages, Etc	.)				
*		St-Arnaud et al., "The <i>int-</i> 1 proto-oncogene is transcriptionally activated during neuroectodermal differentiation of P19 mouse embryonal carcinoma cells", Oncogene, 4(9):1077-1080 (1989)					
	Stearns et al., "Liazarole and 13-cis-Retinoid A (July 1993)	Stearns et al., "Liazarole and 13-cis-Retinoid Acid Anti-Prostatic Tumor Activity", Cancer Research, 53(13):3072-3077 (July 1993)					
		Szeto et al., "Overexpression of the Retinoic Acid-Responsive Gene Stra6 Human Cancers and Its Synergistic Induction by Wnt-1 and Retinoic Acid", Cancer Research, 61:4197-4250 (May 15, 2001)					
	Tetsu et al., "β-Catenin regulates expression o	Tetsu et al., "β-Catenin regulates expression of cyclin D1 in colon carcinoma cells", Nature, 398:422-426 (1999)					
	Tice et al., "Synergistic Induction of Tumor A Expression Profiling", The Journal of Biologic						
	Tremblay et al., "Retinoic Acid Stimulates the Choriocarcinoma JEG-3 Cells", Biol. Reprod.,	Expression of 11β-Hydroxysteroid 60:541-545 (1999)	Dehydrogenase Type 2 in Human				
	Van Ooyen et al., "The nucleotide sequence of coding and non-coding sequences", EMBO J.,		ne; evolutionary conservation of				
	Wade et al., "Regulation of the cholestrol efflu	x gene, ABCA1", Lancet, 357:161	-163 (2001)				
	Wainwright et al., "Isolation of a human gene Drosophila segment polarity mutant wingless"		human and murine int-1 and the				
	Wells et al., "Casette mutagenesis: an efficient 34:315 (1985)	Wells et al., "Casette mutagenesis: an efficient method for generation of multiple mutations at defined sites", Gene,					
	Wodarz et al., "Mechanisms of WNT Signaling						
	Wodicka et al., "Genome-wide expression mor (1997)	Wodicka et al., "Genome-wide expression monitoring in Saccharomyces cerevisiae, Nat. Biotechnol., 15:1359-1367 (1997) Wong et al., "Differential Transformation of Mammary Epithelial Cells by Wnt Genes", Mol. Cell. Biol., 14:6278-628 (1994) Xiang et al., "Expression of Co-stimulatory 4-1BB Ligand Induces Significant Tumor Regression and Protective Immunity", Cancer Biotherapy and Radiopharmaceuticals, 14(5):353-361 (1999) Yamada et al., "Identification of semaphorin E as non-MDR drug resistance gene of human cancers", Proc. Natl. Acac Sci. USA, 94:14713-14718 (1997) Zhang et al., "The Retinoic Acid and cAMP-dependent Up-regulation of 3-O-Sulfotransferase-1 Lwads to a Dramatic Augmentation of Anticoagulantly Active Heparan Sulfate Biosynthesis in F9 Embryonal Carcinoma Cells", J. Biol. Chem., 273:27998-28003 (1998)					
	Augmentation of Anticoagulantly Active Hepa						
	Zhang et al., "Gene Expression Profiles in Nor	mal and Cancer Cells", Science, 27	⁷ 6:1268-1272 (1997)				
	Ziemer et al., "Identification of a Mouse Homo Independent Wnt-1 Responsive Gene", Mol. C		iption Factor as a β-Catenin-				
		· <u></u> -					
			- Address				
			······································				

EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.